Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Utah
Primary Objective To determine Time to Chemotherapy Progression (ie includes time on Tarceva monotherapy and chemotherapy) in advanced NSCLC
Secondary Objectives To evaluate survival and response rate associated with Tarceva treatment To study the frequency of symptom improvement (Lung Cancer Subscale)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Performance status 0-1.
Weight Loss \< 10% in preceding 3 months
Age 18 years and older.
Adjuvant chemotherapy allowed if \> 6 months from protocol entry
Adequate Organ Function
Liver enzymes \< 2X normal, bilirubin = normal
Oxygen saturation\> 89% on room air unless chronically oxygen dependent (not cancer related)
Creatinine \<2.0 mg
You may not be if
Not pregnant or lactating.
No Clinical Brain Metastases
No prior chemotherapy for systemic disease
Imminent need for chemotherapy for impending organ dysfunction is not allowed
Clareo Health | A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
